Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRize Circular Regulatory News (CIRC)

Share Price Information for Rize Circular (CIRC)

Share Price is delayed by 15 minutes
Get Live Data
477.15    4.75 (1.01%)
Bid:
474.75
Ask:
479.55
Spread: 4.80 (1.011%)
Market Cap: -
CIRC Live PriceLast checked at - London Stock Exchange

Intraday Rize Circular Share Chart

Project Reset Completed

5 Dec 2014 07:00

RNS Number : 9210Y
Circle Holdings PLC
05 December 2014
 



 

Circle Holdings plc

("Circle" or the "Company")

 

Project Reset Completed

 

5 December 2014

 

Further to the announcement on 29 October 2014, the Company is pleased to announce that on 3 December 2014 the BVI court sanctioned the scheme of arrangement, and on 4 December the scheme became effective and accordingly the Company completed the acquisition of Circle Partnership Limited ("CPL"). All of the steps in respect of Project Reset, the group's organisational restructuring, have now been completed and the Company now owns 100% of Circle Health Limited and the group's operating entities. As a consequence, all of the intragroup debt of ca. £298 million will be eliminated.

 

Issue of shares

In accordance with the terms of the scheme of arrangement, the Company issued 23,093,930 Convertible Shares of £0.02 each in the Company, to the trustee of Circle Partnership Benefit Trust (the "CPBT"), split in two equal tranches, which shall automatically convert after 18 months and 36 months, respectively, into Ordinary Shares. The Convertible Shares cannot be traded or sold until they have converted into Ordinary Shares.

In addition, under the terms of Project Reset, the Company issued 38,855,367 ordinary shares of £0.02 each in the Company to the CPBT (the "CPBT Ordinary Shares"), which are to be used to satisfy options to be granted under the Company's new share incentivisation plans in accordance with the terms previously approved by the Company's shareholders. Application has been made for the CPBT Ordinary Shares to be admitted to AIM, with admission expected to occur on 8 December 2014 ("Admission"). Upon Admission, the shares will rank pari passu in all respects with the existing Ordinary Shares of the Company and cannot be traded or sold by the CPBT until option holders have exercised their options in accordance with the share plan rules. Initial options to be granted under the Partnership Incentive Plan ("PIP") rules are subject to performance criteria and holding periods determined by the Company's Remuneration Committee. The earliest that options can be exercised under the PIP is 31 December 2015. Options granted under the Management Incentive Plan ("MIP") to the Company's senior management team cannot be exercised until 1 December 2016 and are subject to share price triggers.

After issue of the Convertible Shares and the CPBT Ordinary Shares, the Company will have 23,093,930 Convertible Shares and 224,703,258 Ordinary Shares in issue.

Following the issue of the CPBT Ordinary Shares and the Convertible Shares, the CPBT will hold an interest of 25% in the issued share capital of the Company, with the existing shareholders owning the remaining 75%.

 

Directors' interests

 

Following completion of Project Reset and the grant of options under the MIP, the Directors shall have the following holdings in the Company:

 

Name

 

Title

Number of Convertible Shares

Number of

Ordinary Shares

Total Shares

Michael Kirkwood

Non-Executive Chairman

-

94,157

94,157

Lorraine Baldry

Non-Executive Director

-

47,078

47,078

Andrew Shilston

Non-Executive Director

-

47,078

47,078

Justin Jewitt

Non-Executive Director

-

-

-

Lord John Hutton

Non-Executive Director

-

-

-

Steve Melton

Chief Executive Officer

395,888

*

395,888*

Dr Massoud Fouladi

Chief Medical Officer

2,362,466

**

2,362,466**

Paolo Pieri

Chief Financial Officer

-

***

***

* It is intended that Mr Melton will receive options under the MIP to acquire 3,701,953 Ordinary Shares, which shall be subject to performance conditions.

** It is intended that Mr Fouladi will receive options under the MIP to acquire 2,217,693 Ordinary Shares, which shall be subject to performance conditions.

*** It is intended that Mr Pieri will receive options under the MIP to acquire 1,446,281 Ordinary Shares, which shall be subject to performance conditions. In addition, Mr Pieri has been granted options to acquire 2,200,000 Ordinary Shares outside the MIP, of which 1,100,000 options have vested and 1,100,000 are unvested.

 

Relationship Agreement

 

As previously announced, the CPBT has entered into a Relationship Agreement with the Company, which sets forth the rights and responsibilities of each in relation to CPBT's holding in the Company, including the right of the CPBT to appoint a director to the Company's board of directors. Massoud Fouladi, currently an executive director of the Company, is the CPBT's initial designated director. 

 

New Articles of Association

 

Following the order to sanction the scheme of arrangement, the Company's new articles of association, which were provisionally approved at the Company's AGM in May, have been formally adopted.

 

The Company's Chairman, Michael Kirkwood, commented: "The completion of this organisational restructuring now fully aligns the interests of our external shareholders and our clinicians, managers and staff in our hospitals. Importantly, our hospital and management colleagues now have a substantive share in our listed company which brings the benefits of value transparency and, when vested, liquidity. The unification of interests also reduces the costs associated with running a parallel equity participation for our staff. The Board believes that the material stake in the business held by our clinical partners demonstrably improves motivation, efficiency and compassionate care to the benefit of our patients and thus to our wider community of stakeholders. I welcome all our partners into the shareholding of the Company."

 

Dr. Massoud Fouladi, the CPBT's designated director, added: "Today represents the fulfilment of a long-held ambition for our partnership. These organisational changes strengthen our identity and ethos as a co-owned company, and we hope it creates a blueprint for others to follow. I am privileged to act as the partnership's first designated director."

 

 

 

For further information, please contact:

 

 

Circle Holdings plc

Michael Kirkwood, Chairman +44(0) 20 7034 5258

Steve Melton, Chief Executive Officer

Gordon Hector, Head of Communications

Numis Securities Limited

Michael Meade, Nominated Adviser +44(0) 20 7260 1000

Alex Ham, Corporate Broking

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURQKQDKCBDDFBK
Date   Source Headline
7th Sep 20164:40 pmRNSSecond Price Monitoring Extn
7th Sep 20164:35 pmRNSPrice Monitoring Extension
25th Aug 20167:00 amRNSHalf Year Results for period ended 30 June 2016
16th Aug 20167:00 amRNSCircle selected preferred bidder for MSK service
29th Jun 20167:00 amRNSDevelopment and Management Agreement in China
9th Jun 20164:41 pmRNSHolding(s) in Company
8th Jun 20165:39 pmRNSHolding(s) in Company
8th Jun 20163:07 pmRNSHolding(s) in Company
6th Jun 20161:09 pmRNSConversion of Convertible Shares
18th May 201612:27 pmRNSResult of AGM
17th May 20164:40 pmRNSSecond Price Monitoring Extn
17th May 20164:35 pmRNSPrice Monitoring Extension
26th Apr 20163:03 pmRNSNotice of AGM
1st Apr 20163:58 pmRNSNotification of major interest in shares
30th Mar 20167:00 amRNSFull Year 2015 Audited Results
14th Mar 20164:40 pmRNSSecond Price Monitoring Extn
14th Mar 20164:35 pmRNSPrice Monitoring Extension
9th Feb 20167:00 amRNSTrading Statement
29th Jan 20164:40 pmRNSSecond Price Monitoring Extn
29th Jan 20164:35 pmRNSPrice Monitoring Extension
27th Jan 20167:00 amRNSMovement in Share Price
12th Oct 20157:00 amRNSOperator agreement with CircleHealth for Harley St
12th Oct 20157:00 amRNSStatement regarding new cancer centre
27th Aug 20157:00 amRNSHalf Yearly Report
21st Jul 20154:40 pmRNSSecond Price Monitoring Extn
21st Jul 20154:35 pmRNSPrice Monitoring Extension
26th Jun 20154:40 pmRNSSecond Price Monitoring Extn
26th Jun 20154:35 pmRNSPrice Monitoring Extension
23rd Jun 20157:00 amRNSGrant of Options to Executive Directors
20th May 20151:59 pmRNSResult of AGM
13th May 20154:35 pmRNSPrice Monitoring Extension
5th May 20152:53 pmRNSPOSTING OF ANNUAL REPORT AND AGM
28th Apr 20153:55 pmRNSNotification of major interest in shares
28th Apr 20153:22 pmRNSVoting Rights Announcement
28th Apr 201512:30 pmRNSNotification of major interest in shares
27th Apr 20158:04 amRNSVoting Rights Announcement
24th Apr 20152:37 pmRNSNotification of major interest in shares
24th Apr 20152:15 pmRNSNotification of major interest in shares
16th Apr 201510:20 amRNSNotification of major interest in shares
14th Apr 20157:00 amRNSNotification of major interest in shares
19th Mar 20157:00 amRNSAnnual Financial Report
9th Jan 20157:00 amRNSStatement regarding Hinchingbrooke
6th Jan 20152:27 pmRNSNotification of Major Interest in Shares
12th Dec 20142:52 pmRNSNotification of Major Interest in Shares
11th Dec 20148:30 amRNSNotification of Major Interest in Shares
11th Dec 20148:30 amRNSNotification of Major Interest in Shares
9th Dec 20144:39 pmRNSNotifications of Major Interests in Shares
5th Dec 20147:00 amRNSProject Reset Completed
29th Oct 201412:39 pmRNSApproval of Project Reset by Shareholders
22nd Oct 20149:39 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.